Veri makes a wearable device that tracks blood sugar for non-diabetics, aimed at helping users achieve optimal metabolic health through personalized, continuous monitoring. The device provides real-time feedback on how food and lifestyle choices affect personal metabolism and is described by a company advisor as like having the best nutritionist standing by 24/7. Veri is available in Europe and, as of yesterday, entered the US market; the company reports roughly 50,000 people on a waitlist. Founded in early 2020 by Anttoni Aniebonam, Verneri Jäämuru and Frans Lehmusvaara in Helsinki, Veri positions itself in preventative medicine against a backdrop where only 12% of American adults are metabolically healthy and 78% of those hospitalized for COVID were overweight or obese. The recent $4 million financing will support shipments to US customers and further growth across Europe. Leadership frames the product as an effortless, deeply personalized way of eating to help users reach health goals and prevent chronic disease.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2021